EBS vs. OPK, GERN, INVA, MYGN, RIGL, VSTM, VNDA, IRWD, XOMA, and CDXS
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include OPKO Health (OPK), Geron (GERN), Innoviva (INVA), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Ironwood Pharmaceuticals (IRWD), XOMA (XOMA), and Codexis (CDXS). These companies are all part of the "biotechnology" industry.
Emergent BioSolutions vs.
Emergent BioSolutions (NYSE:EBS) and OPKO Health (NASDAQ:OPK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.
Emergent BioSolutions presently has a consensus price target of $14.33, suggesting a potential upside of 149.93%. OPKO Health has a consensus price target of $2.75, suggesting a potential upside of 51.93%. Given Emergent BioSolutions' higher probable upside, analysts clearly believe Emergent BioSolutions is more favorable than OPKO Health.
OPKO Health has lower revenue, but higher earnings than Emergent BioSolutions. OPKO Health is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
Emergent BioSolutions has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500.
Emergent BioSolutions has a net margin of -18.55% compared to OPKO Health's net margin of -18.65%. OPKO Health's return on equity of -9.76% beat Emergent BioSolutions' return on equity.
OPKO Health received 83 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. However, 66.77% of users gave Emergent BioSolutions an outperform vote while only 65.68% of users gave OPKO Health an outperform vote.
In the previous week, Emergent BioSolutions had 3 more articles in the media than OPKO Health. MarketBeat recorded 14 mentions for Emergent BioSolutions and 11 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.95 beat Emergent BioSolutions' score of 0.28 indicating that OPKO Health is being referred to more favorably in the news media.
78.4% of Emergent BioSolutions shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 1.2% of Emergent BioSolutions shares are owned by insiders. Comparatively, 47.3% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Emergent BioSolutions beats OPKO Health on 9 of the 16 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
This page (NYSE:EBS) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy EBS Stock Free EBS Stock Alerts